Skip to main content
Clinical Trials/NCT03444688
NCT03444688UnknownNot Applicable

Development and Evaluation of a Novel Portable Robotic Gait Rehabilitation Platform in Older Chronic Stroke Survivors (Phase 2)

National University Hospital, Singapore2 sites in 1 country100 target enrollmentStarted: April 2, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Enrollment
100
Locations
2
Primary Endpoint
Berg Balance Scale (BBS)

Study Overview

Brief Summary

The aims of this study is to test the training effects of the robotic walker. This study will compare the effectiveness of 2 different types of gait training protocols in chronic stroke patients, 1) conventional gait training (CT, control group), and 2) gait rehabilitation with the new walker modified after 1st stage (WT, experimental group).

Detailed Description

This will be a prospective single blind randomized control trial where investigators propose to recruit a maximum of 100 older chronic stroke patients (age 50 years to 90 years old) with mild to severe lower limb motor function impairment.

Recruited subjects will have 19 study visits. The recruited 100 subjects will be divided into 2 groups of 50 each through a simple randomization scheme; 1) Conventional gait training (CT, control group) and 2) Gait rehabilitation with the new walker modified after 1st stage (WT, experimental group). Each subject will undergo training programs consisting of 45 minutes training session (excluding rest periods), 3 days (alternate) a week for 6 consecutive weeks.

Subjects allocated to the CT group will receive physiotherapy program, including active assisted or passive range of motion and conventional gait and balance training. The subjects will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. Subjects will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. Among the PNF techniques, investigators will facilitate pelvic motion to improve control and mobility of the subjects. Subjects will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.

For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. The level of BWS will be provided as much as the subjects can support his or her residual body weight (10% to 30% BWS). The BWS force will be gradually reduced as soon as the subjects can support his or her full body weight. The clinical criterion for the reduction is that the subjects show the ability to move his or her hips and are able to support his or her own body weight sufficiently on the affected lower limb and straighten their legs during the single-leg stance phase. Therapists will be able to control the level of BWS force according to the criteria mentioned above. FES will be used to stimulate the peroneal nerve in the affected side, and the intensity of the device will be painlessly controlled by allowing sufficient dorsiflexion and eversion during the swing phase. FES will be set to synchronize with the inertial measurement unit (IMU) sensors and the stimulation timing for the common peroneal nerve will based on the detected gait phase by IMU sensors. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes. The decision on providing resistance or assistance modes will be made according to the subjects' functional ambulation category (FAC) level. For subjects with FAC level less than 3, the assistive function will be implemented, otherwise resistive function will be applied. The assistance and resistance forces will be applied proportional to the BW of the subjects (2% to 7% of BW), which is determined by therapists. The rationale of dividing the WT group into 2 parts of different training is that the 1st part is to provide basic locomotive function with persistent and repetitive sensory stimulation while the 2nd part is to add task-specificity to improve weight-bearing, aerobic, functional strengthening and balance for the neurologically challenged patients by implementing a variety of walking tasks. Investigators expect that the repetitive and persistent walking with task-specific gait training will promote better functional outcomes than the conventional gait therapy.

During the session, subjects can request for a rest anytime if they experience discomfort or fatigue. Additionally, investigators will provide them with a 5 - 15 minutes of rest time. The rest period given depends on individual subjects' needs. Investigators will seek their opinion whether subjects have enough rest and are well to continue with the session. Longer rest period will be given to the subjects who require them. During the resting period and also the period where subjects are not required to participate, a chair will be provided for the subject to sit and rest.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
50 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patient is aged 50 years to 90 years old
  • More than 6 months from first ever stroke but within 5 years confirmed by CT or MRI Brain
  • Mild to severe unilateral motor weakness (hemiparesis has to be severe with lower extremity strength graded as 3 or less on the Medical Research Council scale in more than 2 muscle groups) and severity should be between 5 and 25 calculated according to National Institute of Health Stroke Scale
  • Significant gait deficits ( Functional Ambulation Category , FAC ≤ 4 )
  • Able to understand instructions and participate in rehabilitation
  • Spasticity: Modified Ashworth Scale (MAS) less than 4
  • Independent trunk control
  • Comfortable to walk without a walking aid

Exclusion Criteria

  • Patient undergoing any formal rehabilitation program
  • Multiple stroke
  • Intracranial bleeds
  • Any chronic disabling pathologies
  • Spasticity limiting lower extremity ROM to less than 80 %
  • Mini Mental State Examination (MMSE) score < 24
  • Significant sensory deficit/ hemisensory neglect
  • Any recent surgeries including orthopedic
  • Active cancers or any other terminal illness
  • Significant orthostatic hypotension
  • Hip, knee and ankle arthrodesis
  • Severe vascular disorders in lower limbs
  • Having permanent pacemakers or ventriculoperitoneal shunt
  • Subject's weight > 75kg

Arms & Interventions

CT, Control Group

Active Comparator

Conventional Gait Training

Intervention: Conventional Gait Training (Other)

WT, Experimental Group

Experimental

Gait rehabilitation with walker

Intervention: Gait rehabilitation with walker (Device)

Outcomes

Primary Outcomes

Berg Balance Scale (BBS)

Time Frame: 15 minutes

The Berg Balance Scale (BBS) was developed to measure balance among older people with impairment in balance function by assessing the performance of functional tasks. It is a valid instrument used for evaluation of the effectiveness of interventions and for quantitative descriptions of function in clinical practice and research. Description: 14-item scale designed to measure balance of the older adult in a clinical setting. Equipment needed: Ruler, two standard chairs (one with arm rests, one without), footstool or step, stopwatch or wristwatch, 15 ft walkway Completion: Time: 15-20 minutes Scoring: A five-point scale, ranging from 0-4. "0" indicates the lowest level of function and "4" the highest level of function. Total Score = 56 Interpretation: 41-56 = low fall risk 21-40 = medium fall risk 0 -20 = high fall risk A change of 8 points is required to reveal a genuine change in function between 2 assessments.

Clinical Outcomes Variables Score (COVS)

Time Frame: 20 minutes

The COVS assesses functional mobility across a broad range of neurologic conditions.

Temporal spatial gait analysis (Part 1)

Time Frame: 10 minutes

Gait analysis is assessed by Tekscan Strideway which can provide temporospatial parameters including step length (cm), step width (cm), step time (s), step velocity (cm/s) and stride length (cm).

Functional Ambulation Category (FAC)

Time Frame: 2 minutes

FAC is a functional walking test that evaluates ambulation ability.

National Institute of Health Stroke Scale (NIHSS)

Time Frame: 12 minutes

NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

6 minute walk test

Time Frame: 6 minutes

The 6 Minute Walk Test is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

Temporal spatial gait analysis (Part 2)

Time Frame: 10 minutes

Gait analysis is assessed by Tekscan Strideway which can provide temporospatial parameters including stride time (s), gait cycle time (s), stance time (s), swing time (s), single support time (s), and double support time (s).

Modified Ashworth Scale (MAS)

Time Frame: 3 minutes

Modified Ashworth Scale (MAS) measures resistance during passive soft-tissue stretching. It is a quick and easy measure that can help assess the efficacy of treatment. MAS is performed in the supine position (this will garner the most accurate and the lowest score as any tension anywhere in the body will increase spasticity). Scoring 0 = Normal tone, no increase in tone 1 = Slight increase in muscle tone, manifested by a catch and release or minimal resistance at the end of the range of motion (ROM) when the affected part(s) is moved in flexion or extension 1+ = Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM 2 = More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved 3 = Considerable increase in muscle tone, passive movement difficult 4 = Affected part(s) rigid in flexion or extension

Medical Research Council (MRC) grading

Time Frame: 5 minutes

The muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle.

Timed Up and Go (TUG)

Time Frame: 8 minutes

TUG is a simple test used to assess a person's mobility and requires both static and dynamic balance.

Electromyography (EMG)

Time Frame: 10 minutes

Electromyography (EMG) is evaluated by Delsys Trigno Wireless System which is a non-invasive method to detect muscle activity in mircoamperes. EMG sensors will be placed on Rectus Femoris, Tibilatis Anterior, Biceps Femoris, and lateral Gastrocnemius.

Secondary Outcomes

  • Functional Independence Measure (FIM)(8 minutes)
  • Number of falls(1 year)
  • Revised Nottingham Sensory Assessment (rNSA)(15 minutes)
  • Patient's attitudes towards the robotic walker using visual analogue scale (EQ-5D VAS) ranging from 0 (negative) to 10 (positive).(5 minutes)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Development and Evaluation of a Novel... | Clinical Trial